Product Highlight - ENERZAIR BREEZHALER

01 Dec 2021
Product Highlight - ENERZAIR-BREEZHALER
• The first in class LABA/LAMA/ICS triple asthma inhaler therapy available in Hong Kong.1
• Once daily capsule with inhaler1
• 5 min rapid onset time2
• 42% reduction in annualized rate of asthma severe exacerbations by ENERZAIR® BREEZHALER® (once-daily) as compared to SAL/FLU high-dose (twice-daily).2
• Breezhaler with feedback mechanism to confirm the full dosage delivery1

ENERZAIR® BREEZHALER® = IND/GLY/MF 150/50/160 mcg (once-daily); SAL/FLU high-dose = SAL/FLU 50/500 mcg (twice-daily)

References:
1.
Enerzair HK Prescribing Information [June 2021].
2. Kerstjens H, et al. Lancet Respir Med. 2020;8(10):1000–1012.

Related MIMS Drugs

Editor's Recommendations
Related Diseases